Bionano Genomics moved -2.6% this afternoon session, trading between a high of $0.6991 and a low of $0.6231 per share. Yesterday the stock finished at $0.67 per share, compared to an average analyst target price of $4.06.
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. The small-cap biotechnology: laboratory analytical instruments company is based in the United States, and over the last twelve months it has returned a dividend yield of None%. Bionano Genomics has trailing twelve months earnings per share (EPS) of -0.48, which at today's prices amounts to a price to earnings (P/E) ratio of -1.4.
Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of None. Usually a PEG ratio between 0 and 1 indicates a potentially undervalued company.
Overview of the Company's Gross Margins:
| Date Reported | Revenue ($ k) | Cost of Revenue ($ k) | Gross Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2022-12-31 | 27,802 | 21,857 | 21.38 | -0.74 |
| 2021-12-31 | 17,981 | 14,107 | 21.54 | -33.95 |
| 2020-12-31 | 8,503 | 5,730 | 32.61 | -1.72 |
| 2019-12-31 | 10,130 | 6,768 | 33.18 | n/a |
Bionano Genomics's 27.2% average gross margins are thinner than the 57.74% average of the Biotechnology industry, implying that the firm might be lacking in competitivity.
